Accessibility Statement Skip Navigation
  • Back to Global Sites
  • +972-77-2005042
  • Blog
  • Journalists
  • GDPR
  • Send a Release
PR Newswire: news distribution, targeting and monitoring
  • News
  • Products
  • Contact
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • Telephone

    • +972-77-2005042 from 8 AM - 11 PM IL

    • Contact
    • Contact

      +972-77-2005042
      from 8 AM - 11 PM IL

Close menu
  • News
  • Products
  • Contact
    • Request More Information
    • Journalists
    • GDPR

    IM Cannabis Regains Compliance with Nasdaq Minimum Bid Price Requirement

    IM Cannabis logo

    News provided by

    IM Cannabis Corp.

    23 Sep, 2026, 23:01 IDT

    Share this article

    Share this article


    VANCOUVER and GLIL YAM, Israel, Sept. 23, 2026 /PRNewswire/ -- IM Cannabis Corp. ("IMC" or the "Company") (Nasdaq: IMCC), a medical cannabis company with operations in Israel and Germany, today announced that on September 23, 2026, it received written notice from Nasdaq Stock Market LLC ("Nasdaq"), indicating that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share.

    The Nasdaq staff made this determination of compliance after the closing bid price of the Company's ordinary shares was $1.00 per share or greater for the 18 consecutive business days from August 27 to September 22, 2026. Accordingly, the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2) and Nasdaq considers the bid price deficiency matter now closed.

    About IM Cannabis Corp.

    IMCC (Nasdaq: IMCC) is an international company currently operating a medical cannabis platform serving patients in Israel and, through Adjupharm GmbH, Germany. Following completion of the pending transactions announced by the Company on August 17, 2026, the Company expects to retain its Israeli medical cannabis operations and the German operations will be sold.

    The IMCC ecosystem operates in Israel through its subsidiaries, which import and distribute cannabis to medical patients, leveraging years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies and online platforms in Israel that enable the safe delivery and quality control of IMCC's products throughout the value chain.

    Company Contact:

    Michal Efraty

    Investor & Public Relations
    IM Cannabis Corp.
    [email protected]

    Oren Shuster, Chief Executive Officer
    IM Cannabis Corp.
    [email protected]

    Logo - https://mma.prnewswire.com/media/1742228/IM_Cannabis_Logo.jpg

    SOURCE IM Cannabis Corp.

    Modal title

    Also from this source

    IM Cannabis Corp. Appoints New CEO to Lead Technology-Driven Business Expansion

    IM Cannabis Corp. Appoints New CEO to Lead Technology-Driven Business Expansion

    IM Cannabis Corp. (the "Company") (NASDAQ: IMCC) announced changes to its management and board of directors (the "Board"), including the appointment...

    IM Cannabis Announces Intention to Complete 3:1 Share Consolidation to Support Nasdaq Minimum Bid Price Compliance

    IM Cannabis Announces Intention to Complete 3:1 Share Consolidation to Support Nasdaq Minimum Bid Price Compliance

    IM Cannabis Corp. ("IMC" or the "Company") (Nasdaq: IMCC), a medical cannabis company with operations in Israel, announces that the board of...

    More Releases From This Source

    Contact PR Newswire

    • +972-77-2005042
      from 8 AM - 11 PM IL

    Global Sites

    • APAC
    • APAC - Traditional Chinese
    • Asia
    • Brazil
    • Canada
    • Czech
    • Denmark
    • Finland
    • France
    • Germany

     

    • India
    • Indonesia
    • Israel
    • Italy
    • Mexico
    • Middle East
    • Middle East - Arabic
    • Netherlands
    • Norway
    • Poland

     

    • Portugal
    • Russia
    • Slovakia
    • Spain
    • Sweden
    • United Kingdom
    • United States

    Do not sell or share my personal information:

    • Submit via [email protected] 
    • Call Privacy toll-free: 877-297-8921
    Global Sites
    • Asia
    • Brazil
    • Canada
    • Csezh
    • Denmark
    • Finland
    • France
    • Germany
    • India
    • Israel
    • Italie
    • Mexico
    • Middle East
    • Netherlands
    • Norway
    • Poland
    • Portugal
    • Russia
    • Slovakia
    • Spain
    • Sweden
    • United Kingdom
    • United States
    +972-77-2005042
    from 8 AM - 11 PM IL
    • Terms of Use
    • Privacy Policy
    • Information Security Policy
    • Site Map
    • Cookie Settings
    Copyright © 2026 Cision US Inc.